Floatz logo

Copanlisib

Recurrent Skin Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

39 Active assets in the Recurrent Skin Carcinoma cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
University of Alabama at Birmingham
Phase 4BB
Pembrolizumab
Essen Biotech
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
gsk1120212
Cancer Research UK
Phase 2/3B
Nivolumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2B

View all 50 →

Same molecule, other indications

Copanlisib is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
61 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →